Dan Atar retweeted
Enormously honored and proud to present at the famous “Oxford Master Course in Clinical Trials” alongside some of the World’s most famous trialists: Sir Richard Peto, Sir Rory Collins, Professors Colin Baigent, Jane Armitage, Louise Bowman, Amanda Adler, Peter Jüni.
Dan Atar retweeted
Our new study from #JupiterGroup with @SABOURETCardio @dan_atar @mmamas1973
☀️#IPF and long term prognosis after #PPCI in #STEMI pts.
The association held across both sensitivity analyses: 3-year truncated HR 1.78 (1.23-2.58) and post-discharge landmark HR 1.52 (1.04-2.21). Single centre and observational, so external validation is the next step.
doi.org/10.1055/a-2945-5355
Dan Atar retweeted
What are the latest developments in atrial fibrillation, blood pressure management and cardiovascular prevention?
@dan_atar shares his key takeaways from Hot Lines 8 and 9, where new evidence explored integrated AF care, ablation strategies, exercise interventions, long-term blood pressure control, dementia risk, and prevention in patients with chronic kidney disease.
#ESCCongress
Dan Atar retweeted
Guess who I met today? The friend and expert @dan_atar who brought a “gift” : the printed article of incidental #CAC published in #NatureReview in cardiology #ESCCongress2026
Dan Atar retweeted
A great honor to welcome @ESC_President Thomas Lüscher to Bergen and the NCS Spring Meeting. His talk on AI and the future of cardiovascular medicine was truly thought-provoking.
(Take a look at the Elon Musk quote on the first photo🫣)
Arrived in Tokyo. Huge hospitality @ Tokai University Hospital, by my friend Prof. Shinya Goto, a world renowned clinical scientist. Amazing experience just prior to embarking on the Shinkansen bullet train from Odawara to Fukuoka. My warmest thanks for this incredible reception.
Dan Atar retweeted
Rethinking β-blockers after MI
Our @NEJM Editorial integrates evidence from two recent IPD meta-analyses and outlines the emerging paradigm for β-blockade after MI.
👉 nejm.org/doi/full/10.1056/NE…
➡️ Time for personalized secondary prevention
@Borjaibanez1 @dan_atar @DLBHATTMD
Dan Atar retweeted
At #CVCT2025 I reviewed the nonlinear basic discovery arc underlying clinical development from autologous #CDCs #postMI to #deramiocel for #Duchenne #cardiomyopathy culminating in the blockbuster #HOPE3 trial by @Capricor. Odyssean journey!
@SmidtHeart @CIRMnews @CoalitionDMD
Dan Atar retweeted
Any HCP who is involved in post-MI care: this ESC Webinar may be of interest to you:
#Oslo Center for Clinical Heart Research
# Escardio webinars
Dan Atar retweeted
My @TCTMD LBT interview with @dan_atar and @Borjaibanez1 around REBOOT-CNIC and BETAMI-DANBLOCK trials @escardio
➡️ tctmd.com/videos/beyond-the-…
@Hragy @mirvatalasnag @hvanspall @DrMarthaGulati @purviparwani @SVRaoMD @SandeepNathanMD @iamritu
Dan Atar retweeted
#ESCCongress is almost here!
Don't miss 🔥 Hot Line discussions with 💫 Dr @hvanspall & expert guests: Prof @FaiezZANNAD, Prof @dan_atar, Dr Anna Meta Dyrvig Kristensen, Prof Michael Borger, Prof Udo Bavendiek, Prof @j_rvl & Dr Julie De Backer.
🫀 Cutting-edge insights, straight from this year's conference.
#ESCCongress2025 #ESC2025 #CardioEd
Dan Atar retweeted
#ESCcongress2025 Hotine#3. Two large trials (@RebootTrial (n=8500) & betami+danblock (n=5500 together)) PLUS a metaanalysis of them focused in the subgroup of Pt with mildly reduced LVEF are presented. Stay tuned!!
Dan Atar retweeted
TEN HOT LINES
❤️🔥10 hot line sessions already released by @escardio #ESCcongress
❤️🔥They feature 42 major trials alongside 129 exciting additional studies
❤️🔥Spanish trials lead one of them, highlighitng ⬆️level of scientific research
lnkd.in/d_mQCUJX
@RosselloJavier
#CardioX
Dan Atar retweeted
Check out our webinar on various aspects of cardio-oncology recorded yesterday in Stockholm:
dagensmedisin.no/dmarena/nor…
@dan_atar @CTCPR_ @RigsHeart
Dan Atar retweeted
New ESC WG on Thrombosis consensus statement!
Antithrombotic therapy in patients with congenital bleeding disorders—balancing thrombotic risk with bleeding management.
📖 tinyurl.com/yc2ahtxk
@dan_atar @EditorEHJCVP
#ESCThorombosis
Dan Atar retweeted
Replying to @RosselloXavier @escardio @ESC_Journals @Borjaibanez1 @j_alvarezgarcia @cpgale3 @JavedButler1 @john_munkhaugen @dan_atar @GreggWStone @rafavidalperez @SonEspases @idisbaib
Hopefully our findings, which would be soon revealed alongside the results of the BETAMI-DANBLOCK trial, will contribute to a level of evidence A of future ACS guidelines!
@Borjaibanez1 @S_Raposeiras @JovenesSec @CVCTForum @FaiezZANNAD @GreggWStone @JavedButler1 @hvanspall
Dan Atar retweeted
Since December 2024, The International Scientific Board of our journal has 17 members! We are honored to announce that new members are: @dan_atar , @BorianiGiuseppe , Filippo Crea, @LindeCecilia and Gregory Lip.
We hope that their support will enhance the journal's standing!
Dan Atar retweeted
Thanks again for the invitation to present at the Norwegian Society of Cardiology! Great to see many friends including @BeitnesJan @pmyhre @ThorEdvardsen @dan_atar! Looking forward to collaborate on pragmatic RCTs very soon!
And look at the beautiful venue for the meeting 👇
We are so excited to have you @TorBiering as the key note speaker at the annual Norwegian Society of Cardiology meeting 🇳🇴🙌🏻
Dan Atar retweeted
Elevated #NatriureticPeptides and #troponins are strong predictors of #HF events, but ever wondered if these biomarkers predict worsening cardiac structure & function?
We analyzed NT-proBNP, TnT and TnI in a/w serial echo in ~2000 👤 in #ARIC
Just published in @CircAHA
🧵 /5












































